TrialDiabetes care2022

HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.

Anita Y M Kwan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.